Dipesh Uprety MD FACP
@DipeshUpretyMD
Followers
2K
Following
6K
Statuses
3K
Assistant Prof | Thoracic Oncology 🫁 & Phase-I @karmanoscancer | EIC @BTFCancerNews |Previously @MayoCancerCare @gundersenhealth @JeffHealthAb | Tweets my own
Detroit, MI
Joined June 2018
Pleased to share our study -"Trends in Incidence & Survival Outcomes in Small Cell Lung Cancer Patients" ➡️SCLC cases have gradually declined, now comprising 11.2% of all lung cancers @OncoAlert #LCSM @BTFCancerNews @aniroulaMD
@kaushalpar @thadid1
2
8
29
RT @Tony_Calles: Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of…
0
5
0
Results of a phase II study @NEJM ➡️Pts w/ advanced-stage NRG1 fusion–positive cancer treated with zenocutuzumab ➡️ORR 30% Md DoR 11.1 mo Md PFS 6.8 mo ➡️ORR 29% in NSCLC & 42% in pancreatic cancer ➡️AE: Diarrhea & IRR @OncoAlert #LCSM @BTFCancerNews
1
5
19
RT @aniroulaMD: Incidence of small cell lung cancer have decreased in last 2 decades. Check out this study. @EmoryThoracic @EmoryPCCM @Lung…
0
1
0
➡️The annual age-adjusted SCLC incidence rate also decreased: 9.0 per 100,000 in 2000 to 4.6 in 2020. ➡️The study didn’t show significant improvement in survival outcomes over the last two decades, likely due to a lack of progress in impactful treatment regimens
1
0
0
➡️The annual age-adjusted SCLC incidence rate also decreased: 9.0 per 100,000 in 2000 to 4.6 in 2020. ➡️The study didn’t show significant improvement in survival outcomes over the last two decades, likely due to a lack of progress in impactful treatment regimens
0
0
0
0
0
1
RT @BalazsHalmosMD: Just received this enticing invite for my opinion from famous author and practicing oncologist named… GI Cancer Updates…
0
2
0
RT @OncoAlert: Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoad…
0
12
0
RT @StephenVLiu: Report on NGS in squamous NSCLC @LungCaJournal from Dr. @Joshua_Reuss et al. Detected actionable genomic alterations in 22…
0
31
0
RT @OncoDailyIO: Potential biomarkers of IO therapy in patients of extremes of age - @KhalilChoucair8
@BMJOncolo…
0
5
0
1
0
2
RT @KhalilChoucair8: Our work exploring potential biomarkers of IO-therapy in patients of extremes of age, is now published in @BMJOncology…
0
11
0
RT @IASLC: Adjuvant immunotherapy can help control micro-metastatic disease at the earliest possible stage. But it may not be necessary fo…
0
8
0
RT @PMResearch_UHN: Yesterday was a remarkable day as we celebrated the 40th anniversary of the T-cell receptor discovery with an inspiring…
0
17
0
RT @TLCconference: It’s official: Drs. @StephenVLiu and Tina Cascone are back as co-chairs for their third year at the Texas Lung Cancer Co…
0
7
0
RT @oncologician: F/67 yrs Stg IV NSCLC , ros1 +ve on selpercatinib . x 3 yr - CR on the PET Scan but patient has significant ascites and…
0
3
0
@VivekSubbiah @oncologician @BalazsHalmosMD @LeciaSequist @Alfdoc2 @christine_lovly @FordePatrick @SuyogCancer While disease progression cannot be completed ruled out, this is likely treatment-related. Dose interruption, symptomatic management and possibly reintroduction with reduced dose with close monitoring of the disease.
0
0
5
RT @TLCconference: We’re excited to announce the 80+ faculty presenting at #TexasLung25 this April! Join us for this 2-day #CE accredited c…
0
8
0